Eli Lilly and Co. (NYSE:LLY) on Thursday released promising long-term data regarding its treatment for Crohn’s disease.
This news comes as the company reported that more than 90% of patients maintained steroid-free remission for three years with Omvoh (mirikizumab-mrkz).
The latest data from Eli Lilly’s Phase 3 VIVID-2 study revealed clinical remission of 92.4%, and Corticosteroid-free clinical remission of 91.2%.
Additional data presented from the Phase 3 VIVID-1 (Crohn’s disease) and LUCENT-3 (Ulcerative colitis UC) trials showed Omvoh-treated patients experienced minimal hospitalizations and surgeries across both major types of inflammatory bowel disease (IBD).
In VIVID-1, Omvoh reduced Crohn’s disease-related hospitalizations and/or surgeries by nearly half versus placebo in the first 12 weeks (incidence rate: 16.9 vs. 30.9 per 100 patient-years), and by nearly 70% during weeks 12 to 52 (4.5 vs. 14.0).
In LUCENT-3, one UC-related hospitalization and no UC-related surgeries were reported by patients treated with Omvoh during the three-year long-term extension.
In the context of this data, Omvoh stands out as the only IL-23p19 inhibitor to demonstrate durable efficacy over extended periods, with significant improvements in bowel urgency and overall disease control.
This positions Eli Lilly favorably in the competitive landscape of treatments for inflammatory bowel disease.
In January 2025, the U.S Food and Drug Administration (FDA) approved Omvoh for moderately to severely active Crohn’s disease in adults.
Technical Analysis
Currently, the stock is trading 1.7% below its 20-day simple moving average (SMA) and 4.3% above its 100-day SMA, indicating a mixed short-term trend but longer-term strength.
Over the past 12 months, shares have increased 17.19% and are currently positioned closer to their 52-week highs, reflecting a strong upward trajectory.
The RSI is at 46.60, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at -6.7903, below its signal line at -4.8820, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $1088.50
- Key Support: $1012.50
Sector Performance
Eli Lilly is currently outperforming its sector, with a slight gain of 0.02% compared to the Healthcare sector’s flat performance of 0.00%.
The Healthcare sector is ranked 5 out of 11 sectors, indicating a mid-tier performance, and has seen a slight decline of 0.63% over the past 30 days.
Despite the recent stability, the sector has shown a modest increase of 1.29% over the past 90 days, suggesting a potential recovery trend.
Eli Lilly’s positive news regarding Omvoh may further bolster its position within the sector as it continues to innovate in treatment options.
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Eli Lilly, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 3.69 — Stock is trading at a premium compared to peers.
- Quality Rank: 94.09 — Indicates a strong balance sheet and operational efficiency.
- Momentum Rank: 82.03 — Stock is outperforming the broader market.
The Verdict: Eli Lilly’s Benzinga Edge signal reveals a strong position in the market, particularly with its momentum score indicating robust performance. However, the low value rank suggests that investors should be cautious about potential overvaluation as the stock continues to rise.
LLY Price Action: Eli Lilly shares were up 0.02% at $1023.45 during premarket trading on Friday, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments